The study of neurotransmitter interactions using positron emission tomography and functional coupling

Clinical Neuropharmacology

Volumn 19, Issue 5, 1996, Pages 371-389

  Schloesser, Ralf ^a   Simkowitz, Philip ^a   Bartlett, Elsa J ^a   Wolkin, Adam ^b   Smith, Gwenn S ^a   Dewey, Stephen L ^c   Brodie, Jonathan D ^a,d  

^a NEW YORK UNIVERSITY   (United States)

^b Veterans Administration   (United States)

^c BROOKHAVEN NATIONAL LABORATORY   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Brain imaging; Interaction; Neuroleptics; Neurotransmitter; Positron emission tomography; Schizophrenia

Indexed keywords

3 METHYLSPIPERONE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALTANSERIN; BENZODIAZEPINE; BROMOSPIPERONE; CARBON 11; CARFENTANIL; CLOZAPINE; COCAINE; DIPRENORPHINE; DOPAMINE 2 RECEPTOR; EPLIVANSERIN; ETHYLBENZTROPINE; FLUMAZENIL; FLUORODEOXYGLUCOSE F 18; HALOPERIDOL; KETANSERIN; LISURIDE; LORAZEPAM; METHYLPHENIDATE; NEUROLEPTIC AGENT; NICOTINE; OXYGEN 15; PIMOZIDE; RACLOPRIDE; SCOPOLAMINE; SEROTONIN ANTAGONIST; TIOTIXENE; UNINDEXED DRUG;

ADULT; BRAIN BLOOD FLOW; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; GLUCOSE METABOLISM; HUMAN; IMAGE ANALYSIS; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIGAND BINDING; MALE; MENTAL DISEASE; NEUROTRANSMISSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA;

EID: 0029789970     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619050-00001     Document Type: Review

References (120)

1. Janssen PAJ, Niemegeers CJE, Schellekens KHL. Is it possible to predict the clinical effects of neuroleptic drugs (major tranquilizers) from animal data? Part I. "Neuroleptic activity spectra" for rats. Arzneimittelforschung 1965;15:104-17.
2. Da Prada M, Cesura AM, Launay JM, Richards JG. Platelets as a model for neurones? Experientia 1988;44:115-26.
3. Gold PW, Chrousos GP. Clinical studies with corticotropin releasing factor: implications for the diagnosis and pathophysiology of depression, Cushing's disease and adrenal insufficiency. Psychoneuroendocrinology 1985;10:401-19.
4. Meltzer HY, So R, Miller RJ, Fang VS. Comparison of the effects of substituted benzamides and standard neuroleptics on the binding of 3-H-spiroperidol in the rat pituitary and striatum with in vivo effects on rat prolactin secretion. Life Sci 1979;24:573-84.
5. Pickar D, Labarca R, Doran AR, et al. Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment. Arch Gen Psychiatry 1986;43:669-76.
6. Pickar D. Perspective on a time dependent model of neuroleptic action. Schizophr Bull 1988;14:255-68.
7. Hermann WM, Irrgang U. An absolute must in clinico-pharmacological research: pharmacoelectroencephalography, its possibilities and limitations. Pharmacopsychiatry 1983;16:134-42.
8. Phelps ME, Mazziotta JC, Schelbert HR. Positron emission tomography and autoradiography. New York: Raven Press, 1986.
9. Reivich M, Alavi A. Positron emission tomography. New York: Raven Press, 1985.
10. Phelps ME, Huang S, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurements of local cerebral glucose metabolic rate in humans with [11F]2-fluoro-2-D-deoxyglucose: validation of method. Ann Neurol 1979;6:371-88.
11. Buchsbaum MS, Ingvar DH, Kessler R, et al. Cerebral glucography with positron emission tomography. Arch Gen Psychiatry 1982;39:251-9.
12. Farkas T, Wolf A, Jaeger J, Brodie JD, Christman DR, Fowler JS. Regional brain glucose metabolism in chronic schizophrenia: a positron emission transaxial tomographic study. Arch Gen Psychiatry 1984;41:293-300.
13. Bartlett EJ, Brodie JD, Wolf AP, Christman DR, Laska E, Meissner M. Reproducibility of cerebral glucose metabolic measurements in resting human subjects. J Cereb Blood Flow Metab 1988;8:502-12.
14. Bartlett EJ, Barouche F, Brodie JD, et al. Stability of resting deoxyglucose metabolic values in PET studies of schizophrenia. Psychiatry Res 1991;40:11-20.
15. Wang G-J, Volkow ND, Wolf AP, Brodie JD, Hitzmann RJ. Intersubject variability of brain glucose metabolic measurements in young normal males. J Nucl Med 1994;35:1457-66.
16. DeLisi LE, Holcomb HH, Cohen RM, et al. Positron emission tomography in schizophrenic patients with and without neuroleptic medication. J Cereb Blood Flow Metab 1985;5:201-6.
17. Wolkin A, Jaeger J, Brodie JD, et al. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. Am J Psychiatry 1985;142:564-71.
18. Szechtman HJ, Nahmias C, Garnett ES, et al. Effects of neuroleptics on altered cerebral glucose metabolism in schizophrenia. Arch Gen Psychiatry 1988;45:523-32.
19. Wik G, Wiesel FA, Sjogren I, Blomqvist G, Greitz T, Stone-Elander S. Effects of sulpiride and chlorpromazine on regional cerebral glucose metabolism in schizophrenic patients as determined by positron emission tomography. Psychopharmacology 1989;97:309-18.
20. Bartlett EJ, Wolkin A, Brodie JD, Laska EM, Wolf AP, Sanfilipo M. Importance of pharmacologic control in PET studies: effects of thiothixene and haloperidol on cerebral glucose utilization in chronic schizophrenia. Psychiatry Res 1991;40:115-24.
21. Buchsbaum MS, Potkin SG, Marshall JF, et al. Effects of clozapine and thiothixene on glucose metabolic rate in schizophrenia. Neuropsychopharmacology 1992;6:155-64.
22. Volkow ND, Brodie JD, Wolf AP, Angrist B, Russell J, Cancro R. Brain metabolism in patients with schizophrenia before and after acute neuroleptic administration. J Neurol Neurosurg Psychiatry 1986;49:1199-202.
23. Wolkin A, Barouche F, Wolf AP, et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am J Psychiatry 1989;146:905-8.
24. Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993;33:227-35.
25. Friedhoff AJ. A dopamine-dependent restitutive system for the maintenance of mental normalcy. Ann NY Acad Sci 1986;463:47-52.
26. Davila R, Manero E, Zumarraga M, Andia I, Schweitzer JW, Friedhoff AJ. Plasma homovanillic acid as a predictor of response to neuroleptics. Arch Gen Psychiatry 1988;45:564-7.
27. 2-dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology (Berl) 1992;106:433-8.
28. Bartlett EJ, Brodie JD, Simkowitz P, et al. Time dependent effects of a haloperidol challenge on energy metabolism in the normal human brain. Psychiatry Res 1996;60:91-9.
29. Schlyer DJ, Volkow ND, Fowler JS, et al. Regional distribution and kinetics of haloperidol binding in human brain: a PET study with [18F]haloperidol. Synapse 1992;11:10-9.
30. Wagner HN Jr, Burns HD, Dannals RF, et al. Imaging dopamine receptors in the human brain by positron tomography. Science 1983;221:1264-6.
31. Maziere B, Loc'h C, Baron JC, et al. In vivo quantitative imaging of dopamine receptors in human brain using positron emission tomography and [76Br]bromospiperone. Eur J Pharmacol 1985;114:267-72.
32. Martinot JL, Paill'ere-Martinot ML, Loc'h C, et al. The estimated density of D2 striatal receptors in schizophrenia. A study with positron emission tomography and 76Br-bromolisuride. Br J Psychiatry 1991;158:346-50.
33. Baron JC, Comar D, Zarifian E, et al. Dopaminergic receptor sites in human brain: positron emission tomography. Neurology 1985;35:16-24.
34. Farde L, Ehrin E, Eriksson L, et al. Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography. Proc Natl Acad Sci USA 1985;82:3863-7.
35. Farde L, Halldin C, Stone-Elander S, Sedvall G. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology (Berl) 1987;92:278-84.
36. Volkow ND, Fowler JS, Wang GJ, et al. Decreased dopamine transporters with age in health human subjects. Ann Neurol 1994;36:237-9.
37. Fowler JS, Volkow ND, Wolf AP, et al. Mapping cocaine binding sites in human and baboon brain in vivo. Synapse 1989;4:371-7.
38. Ding YS, Fowler JS, Volkow ND, et al. Pharmacokinetics and in vivo specificity of [11C]DL-threo-methylphenidate for the presynaptic dopaminergic neuron. Synapse 1994;18:152-60.
39. Farde L, Halldin C, Muller L, Suhara T, Karlsson P, Hall H. PET study of [11C]beta-CIT binding to monoamine transporters in the monkey and human brain. Synapse 1994;16:93-103.
40. Biver F, Goldman S, Luxen A, et al. Multicompartmental study of fluorine-18 altanserin binding to brain 5HT2 receptors in humans using positron emission tomography. Eur J Nucl Med 1994;21:937-46.
41. 2 receptor antagonist. In: Hartmann A, Hoyer S, eds. Cerebral blood flow and metabolism measurements. Berlin: Springer Verlag, 1985;pp. 471-80.
42. Dewey SL, Tan P, Smith GS, et al. PET and in vivo microdialysis studies of SR 46349B, a new and selective 5-HT2 antagonist [Abstract]. 24th Ann Mtg Soc for Neuroscience, pt 2, 1994;20:1552.
43. Dewey SL, MacGregor RR, Brodie JD, et al. Mapping muscarinic receptors in human and baboon brain using [N-11C-methyl]-benztropine. Synapse 1990;5:213-23.
44. 11C]scopolamine and positron emission tomography. J Cereb Blood Flow Metab 1992;12:147-54.
45. 11C]Tropanyl benzilate-binding to muscarinic cholinergic receptors: methodology and kinetic modeling alternatives. J Cereb Blood Flow Metab 1994;14:85-99.
46. Nordberg A, Hartvig P, Lilja A, et al. Nicotine receptors in the brain of patients with Alzheimer's disease. Studies with 11C-nicotine and positron emission tomography. Acta Radiol [Suppl] 1991;376:165-6.
47. Nyback H, Halldin C, Ahlin A, Curvall M, Eriksson L. PET studies of the uptake of (S)- and (R)-[11C]nicotine in the human brain: difficulties in visualizing specific receptor binding in vivo. Psychopharmacology (Berl) 1994;115:31-6.
48. Persson A, Ehrin E, Eriksson L, et al. Imaging of [11C|-labelled Ro 15-1788 binding to benzodiazepine receptors in the human brain by positron emission tomography. J Psychiatr Res 1985;19:609-22.
49. Shinotoh H, Yamasaki T, Inoue O, et al. Visualization of specific binding sites of benzodiazepine in human brain. J Nucl Med 1986;27:1593-9.
50. Pappata S, Samson Y, Chavoix C, Prenant C, Maziere M, Baron JC. Regional specific binding of [11C]RO 15 1788 to central type benzodiazepine receptors in human brain: quantitative evaluation by PET. J Cereb Blood Flow Metab 1988;8:304-13.
51. d'Argy R, Gillberg PG, Stalnacke CG, et al. In vivo and in vitro receptor autoradiography of the human brain using an 11C-labelled benzodiazepine analogue. Neurosci Lett 1988;85:304-10.
52. Shinotoh H, Iyo M, Yamada T, et al. Detection of benzodiazepine receptor occupancy in the human brain by positron emission tomography. Psychopharmacology (Berl) 1989;99:202-7.
53. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab 1991;11:735-44.
54. Iyo M, Itoh T, Yamasaki T, et al. Quantitative in vivo analysis of benzodiazepine binding sites in the human brain using positron emission tomography. Neuropharmacology 1991;30:207-15.
55. Frey KA, Holthoff VA, Koeppe RA, Jewett DM, Kilbourn MR, Kuhl DE. Parametric in vivo imaging of benzodiazepine receptor distribution in human brain. Ann Neurol 1991;30:663-72.
56. Debruyne D, Abadie P, Barre L, et al. Plasma pharmacokinetics and metabolism of the benzodiazepine antagonist [11C]Ro 15-1788 (flumazenil) in baboon and human during positron emission tomography studies. Eur J Drug Metab Pharmacokinet 1991;16:141-52.
57. Abadie P, Baron JC, Bisserbe JC, et al. Central benzodiazepine receptors in human brain: estimation of regional Bmax arid KD values with positron emission tomography. Eur J Pharmacol 1992;213:107-15.
58. 11C]flumazenil. J Cereb Blood Flow Metab 1993;13:656-67.
59. 11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab 1995;15:152-65.
60. 11C]flumazenil, and a single-experiment protocol. J Cereb Blood Flow Metab 1995;15:284-300.
61. Frost JJ, Wagner HN Jr, Dannals RF, et al. Imaging opiate receptors in the human brain by positron tomography. J Comput Assist Tomogr 1985;9:231-6.
62. Sadzot B, Mayberg HS, Frost JJ. Detection and quantification of opiate receptors in man by positron emission tomography. Potential applications to the study of pain. Neurophysiol Clin 1990;20:323-34.
63. Sadzot B, Mayberg HS, Frost JJ. Imaging opiate receptors in the human brain with positron emission tomography. Potential applications for drug addiction research. Acta Psychiatr Belg 1990;90:9-19.
64. 11C]diprenorphine cerebral kinetics in man acquired by PET using presaturation, pulse-chase and tracer-only protocols. J Neurosci Methods 1994;51:123-34.
65. Cohen RM, Carson RE, Channing M, et al. 18F-Cyclofoxy PET imaging in man [Abstract]. J Nucl Med 1988;29:796.
66. Fowler JS, MacGregor RR, Wolf AP, et al. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Science 1987;235:481-5.
67. Tedroff J, Aquilonius SM, Hartvig P, et al. Monoamine re-uptake sites in the human brain evaluated in vivo by means of 11C-nomifensine and positron emission tomography: the effects of age and Parkinson's disease. Acta Neurol Scand 1988;77:192-201.
68. Yanai K, Watanabe T, Yokoyama H, et al. Histamine H1 receptors in human brain visualized in vivo by [11C]doxepin and positron emission tomography. Neurosci Lett 1992;137:145-8.
69. Villemagne VL, Dannals RF, Sanchez-Roa PM, et al. Imaging histamine H1 receptors in the living human brain with carbon-11-pyrilamine. J Nucl Med 1991;32:308-11.
70. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986;231:258-61.
71. Coppens HJ, Slooff CJ, Paans AM, Wiegman T, Vaalburg W, Korf J. High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy-resistant schizophrenic patients. Biol Psychiatry 1991;29:629-34.
72. Farde L, Nordstrom AL, Nyberg S, Haildin C, Sedvall G. D1-. D2-, and 5-HT2-receptor occupancy in clozapine-treated patients. J Clin Psychiatry 1994;55(suppl B):67-9.
73. Wong DF, Wagner HN Jr, Tune LE, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 1986;234:1558-63.
74. 2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry 1987;44:671-2.
75. Andreasen NC, Carson R, Diksic M, et al. Workshop on schizophrenia, PET, and dopamine D2 receptors in the human neostriatum [Review]. Schizophr Bull 1988;14:471-84.
76. Tune LE, Wong DF, Pearlson G, et al. Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone. Psychiatry Res 1993;49:219-37.
77. Seeman P, Guan HC, Niznik HB. Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain. Synapse 1989;3:96-7.
78. Young LT, Wong DF, Goldman S, et al. Effects of endogenous dopamine on kinetics of [3H]N-methylspiperone and [3H]raclopride binding in the rat brain. Synapse 1991;9:188-94.
79. Seeman P, Niznik HB, Guan HC. Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride [Letter]. Arch Gen Psychiatry 1990;47:1170-2.
80. Logan J, Dewey SL, Wolf AP, et al. Effects of endogenous dopamine on measures of [18F]N-methylspiroperidol binding in the basal ganglia: comparison of simulations and experimental results from PET studies in baboons. Synapse 1992;9:195-207.
81. Volkow ND, Wang GJ, Fowler JS, et al. Imaging endogenous dopamine competition with [11C]-raclopride in the human brain. Synapse 1994;16:255-62.
82. Seeman P, Guan HC, Van Tol HH. Dopamine D4 receptors elevated in schizophrenia. Nature 1993;365:441-5.
83. 11C]-methylspiperone [Abstract], Psychiatry Res Neuroimaging 1995;61:67-83.
84. Crow TJ. Molecular pathology of schizophrenia: more than one disease process. Br Med J 1980;280:66-8.
85. Friedhoff AJ, Simkowitz P. A new conception of the relationship between psychological coping mechanisms and biological stress buffering systems. Br J Psychiatry [Suppl] 1989;4:61-6.
86. Farde L, Hall H, Pauli S, Halldin C. Variability in D2-dopamine receptor density and affinity, a PET study with 11C raclopride in man. Synapse 1995;20:200-8.
87. Carlsson M, Carlsson A. Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophr Bull 1990;16:425-32.
88. Kubota Y, Inagaki S, Kito S, Wu JY. Dopaminergic axons directly make synapses with GABAergic neurons in the rat neostriatum. Brain Res 1987;406:147-56.
89. Dewey SL, Brodie JD, Fowler JS, et al. Positron emission tomography (PET) studies of dopaminergic/cholinergic interactions in the baboon brain. Synapse 1990;6:321-7.
90. Dewey SL, Wolf A, Fowler J, et al. The effects of central cholinergic blockade on 18F-N-methylspiroperidol binding in the human brain. XVI CINP Congress 1988;96:162.
91. Dewey SL, Smith GS, Logan J, et al. Effects of central cholinergic blockade on striatal dopamine release measured with positron emission tomography in normal human subjects. Proc Natl Acad Sci USA 1993;90:11816-20.
92. Bunney BS, Aghajanian GK. Dopaminergic influence in the basal ganglia: evidence for striatonigral feedback regulation. Res Publ Assoc Res Nerv Ment Dis 1976;55:249-67.
93. McGeer PL, Eccles JC, McGeer EG. Molecular neurobiology of the mammalian brain. New York: Plenum, 1987.
94. Coyle JT, Snyder SH. Antiparkinsonian drugs: inhibition of dopamine uptake in the corpus striatum as a possible mechanism of action. Science 1969;166:809-11.
95. Dewey SL, Smith GS, Logan J, et al. Serotonergic modulation of striatal dopamine measured with positron emission tomography. J Neurosci 1995;15:821-9.
96. Smith GS, Dewey SL, Logan J, et al. The serotonin-dopamine interaction measured with positron emission tomography (PET) and C-11 raclopride in normal human subjects [Abstract]. J Nucl Med 1994;35:85p.
97. Dewey SL, Smith GS, Logan J, et al. GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography. J Neurosci 1992;12:3773-80.
98. Wolkowitz OM, Pickar D. Benzodiazepines and the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991;148:714-26.
99. Kalivas PW, Duffy P, Eberhardt H. Modulation of A10 dopamine neurons by gamma-aminobutyric acid agonists. J Pharmacol Exp Ther 1990;253:858-66.
100. Gale K, Casu M. Dynamic utilization of GABA in substantia nigra: regulation by dopamine and GABA in the striatum, and its clinical and behavioral implications. Mol Cell Biochem 1981;39:369-405.
101. Tandon R, Greden JF. Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 1989;46:745-53.
102. Tandon R, Shipley JE, Greden JF, Mann NA, Eisner WH, Goodson JA. Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms. Schizophr Res 1991;4:23-30.
103. Goldberg TE, Weinberger DR, Pliskin NH, Berman KF, Podd MH. Recall memory deficit in schizophrenia. A possible manifestation of prefrontal dysfunction. Schizophr Res 1989;2:251-7.
104. Saykin AJ, Gur RC, Gur RE, et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry 1991;48:618-24.
105. Dewey SL, Smith GS, Logan J, Brodie JD. Modulation of central cholinergic activity by GABA and serotonin: PET studies with 11C-benztropine in primates. Neuropsychopharmacology 1993;8:371-6.
106. Scatton B, Bartholini C. Modulation of GABA by cholinergic transmission in the rat brain. Brain Res 1980;183:211-6.
107. Arora RC, Meltzer HY. Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm 1991;85:19-29.
108. Meltzer HY. Biological studies in schizophrenia. Schizophr Bull 1987;13:77-111.
109. Consolo S, Ladinsky H, Tirelli AS, Crunelli V, Samanin R, Garattini S. Increase in rat striatal acetylcholine content by D-fenfluramine, a serotonin releaser. Life Sci 1979;25:1975-81.
110. Samanin R, Quattrone A, Peri G, Ladinsky H, Consolo S. Evidence of an interaction between serotoninergic and cholinergic neurons in the corpus striatum and hippocampus of the rat brain. Brain Res 1978;151:73-83.
111. Fristen KJ, Frith CD, Liddle PF, Frackowiak RS. Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab 1991;11:690-9.
112. Volkow ND, Brodie JD, Wolf AP, et al. Brain organization in schizophrenia. J Cereb Blood Flow Metab 1986;6:441-6.
113. Bartlett EJ, Brown JW, Wolf AP, Brodie JD. Correlations between glucose metabolic rates in brain regions of healthy male adults at rest and during language stimulation. Brain Lang 1987;32:1-18.
114. Moeller JR, Strother SC, Sidtis JJ, Rottenberg DA. Scaled Subprofile Model: a statistical approach to the analysis of functional patterns in positron emission tomographic data. J Cereb Blood Flow Metabol 1987;7:649-58.
115. Friston KJ, Frith CD, Liddle PF, Frackowiak RS. Functional connectivity: the principal-component analysis of large (PET) data sets. J Cereb Blood Flow Metab 1993;13:5-14.
116. Levy AV, Brodie JD, Russell AG, Volkow ND, Laska E, Wolf AP. The metabolic centroid method for PET brain image analysis. J Cereb Blood Flow Metab 1989;9:388-97.
117. Levy AV, Laska E, Brodie JD, Volkow ND, Wolf AP. The spectral signature method for the analysis of PET brain images. J Cereb Blood Flow Metab 1991;11:A103-13.
118. Levy AV, Gomez-Mont F, Volkow ND, Corona JF, Brodie JD, Cancro R. Spatial low frequency pattern analysis in positron emission tomography: a study between normals and schizophrenics. J Nucl Med 1992;33:287-95.
119. Davila R, Zumarraga M, Friedhoff AJ, Miller JC. Characteristics of the adaptive aspects of the dopaminergic system. Psychopharmacol Bull 1988;24:338-40.
120. Alexander GE, Crutcher MD, DeLong MR. Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 1990;85:119-46.